← All trials
NCT06260891
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2025
- Primary completion
- Jul 31, 2027
- Completion date
- Dec 31, 2027
- First posted
- Feb 15, 2024
- Last posted
- Nov 7, 2024
- Enrollment
- 34
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- University of PennsylvaniaCollaborator
- University of PennsylvaniaCollaborator
- The American Society of HematologyCollaborator
- University of California, San FranciscoOfficial
- University of CincinnatiCollaborator
- Georgetown UniversityCollaborator
- Newark Beth Israel Medical CenterCollaborator
- Thomas Jefferson UniversityCollaborator
- Duke UniversityCollaborator
- Baylor UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.